As per Intent Market Research, the Plasma Protein Therapeutics Market was valued at USD 23.1 Billion in 2024-e and will surpass USD 40.7 Billion by 2030; growing at a CAGR of 9.9% during 2025 - 2030.
The plasma protein therapeutics market is witnessing robust growth, driven by the increasing prevalence of chronic diseases, such as hemophilia, immunodeficiency disorders, and neurological conditions. Plasma protein therapeutics, including immunoglobulins, albumin, and coagulation factor concentrates, are essential in treating various disorders that stem from protein deficiencies. The market is expanding due to advancements in manufacturing processes and an increasing demand for innovative treatments. Plasma protein products are derived from human plasma, and their therapeutic benefits are crucial for managing life-threatening diseases, especially in patients who require long-term care. Additionally, the rising adoption of home care treatment options and increasing healthcare access are contributing to the market’s expansion.
As the healthcare sector continues to embrace personalized and targeted treatments, plasma protein therapeutics are becoming indispensable in modern medical practices. The growing global focus on rare diseases and immune system disorders, along with advancements in diagnostic technologies, is driving demand for these life-saving therapies. The market is further benefiting from increasing awareness of conditions like hemophilia and immunodeficiencies, which require lifelong treatment and management with plasma-derived therapies.
Immunoglobulins (Ig) Lead Market Due to Versatility and Broad Application
Immunoglobulins (Ig) are the largest segment within the plasma protein therapeutics market, owing to their broad therapeutic applications and high demand across multiple medical conditions. Immunoglobulins, primarily used in the treatment of immunodeficiency disorders, autoimmune diseases, and neurological conditions, play a pivotal role in boosting the immune response. They are derived from human plasma and contain antibodies that can fight infections and modulate immune system function. Immunoglobulins are commonly administered to patients with conditions such as primary immune deficiency, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy (CIDP), among others.
The versatility of immunoglobulins is a key factor driving their dominance in the plasma protein therapeutics market. Their use in treating both inherited and acquired immunodeficiency conditions has expanded over the years, and with an increasing global focus on rare and complex diseases, the demand for immunoglobulins is expected to rise. The growing preference for intravenous (IV) and subcutaneous (SC) routes of administration for immunoglobulins, especially with the advent of at-home treatment options, is further augmenting their market growth.
Albumin Market Experiences Rapid Growth Due to Rising Demand in Liver Disease and Trauma Treatment
The Albumin segment is experiencing significant growth and is anticipated to be one of the fastest-growing segments in the plasma protein therapeutics market. Albumin is a vital protein that helps maintain the osmotic pressure of blood and is essential in treating patients suffering from liver diseases, burns, and trauma-related conditions. Albumin therapy is also used for managing hypoalbuminemia, a condition characterized by low albumin levels, which can result from liver cirrhosis, nephrotic syndrome, or other medical conditions.
The rising prevalence of liver diseases, such as cirrhosis and liver failure, as well as an increase in trauma cases and surgeries, is significantly driving the demand for albumin therapies. Additionally, albumin is increasingly being used in critical care settings and intensive care units (ICUs) to stabilize patients undergoing major surgeries or experiencing severe trauma. The growing number of patients with liver diseases and trauma-related complications is expected to continue fueling the demand for albumin-based therapies in the coming years, making it one of the fastest-growing segments in the market.
Hemophilia Treatment Drives Coagulation Factor Concentrates Demand
The Coagulation Factor Concentrates segment plays a crucial role in the treatment of hemophilia, a rare genetic bleeding disorder. Coagulation factor concentrates, such as Factor VIII and Factor IX, are vital for patients with hemophilia, enabling them to manage bleeding episodes and prevent long-term joint and muscle damage. Hemophilia is most common in males and requires lifelong treatment with coagulation factor concentrates to prevent spontaneous bleeding and manage bleeding episodes resulting from trauma or surgery.
The increasing awareness of hemophilia and advancements in coagulation factor concentrate therapies have led to improved patient outcomes and life expectancy. Additionally, the rising focus on personalized medicine and the development of novel factor concentrates, including extended half-life products, is driving the demand for these therapies. With the growing global population of hemophilia patients, especially in emerging economies, the coagulation factor concentrates market is expected to grow significantly in the coming years.
Hospitals Dominate as Key End-User for Plasma Protein Therapeutics
Hospitals are the largest end-users of plasma protein therapeutics, primarily because they provide critical care for patients suffering from conditions like hemophilia, immunodeficiencies, and liver diseases. Hospitals are equipped with the necessary infrastructure and expertise to manage complex medical cases that require plasma-derived therapies. These institutions provide intravenous (IV) treatments and oversee the administration of immunoglobulins, albumin, and coagulation factor concentrates, ensuring patient safety and monitoring for any adverse reactions during treatment.
Moreover, the increasing prevalence of chronic diseases and the need for specialized treatments are driving the hospital segment’s dominance. With more hospitals adopting advanced therapies and integrating new treatment protocols for diseases like hemophilia, immunodeficiencies, and autoimmune disorders, the hospital segment will continue to lead the market. Hospitals are also pivotal in educating patients about the availability of home care treatment options, which are contributing to the increasing adoption of plasma protein therapies in the home care setting.
North America Leads the Plasma Protein Therapeutics Market
North America is the leading region in the plasma protein therapeutics market, accounting for a significant share due to the high demand for advanced treatments in the United States and Canada. The region has a well-established healthcare infrastructure, widespread access to advanced plasma-derived therapies, and a high level of awareness regarding conditions like hemophilia, immunodeficiency disorders, and liver diseases. Additionally, the presence of major pharmaceutical companies and plasma protein therapeutic providers in North America has contributed to the region’s dominance.
The increasing prevalence of chronic diseases and rare genetic disorders, coupled with a growing focus on improving healthcare access, has made North America the largest market for plasma protein therapeutics. Moreover, advancements in home care options and the availability of subcutaneous (SC) immunoglobulin therapies in the region are expected to drive further market growth. The U.S. healthcare system's focus on high-quality care, reimbursement policies, and advanced treatment protocols will continue to support the dominance of North America in the global plasma protein therapeutics market.
Competitive Landscape and Leading Companies
The plasma protein therapeutics market is highly competitive, with major players focusing on expanding their product portfolios and enhancing therapeutic offerings. Leading companies in the market include Grifols, CSL Behring, Octapharma, Shire (now part of Takeda Pharmaceutical Company), Baxter International, Biotest AG, LFB S.A., and Kedrion Biopharma. These companies have a strong presence in the development, manufacturing, and commercialization of plasma-derived therapies such as immunoglobulins, albumin, and coagulation factor concentrates.
The competitive landscape is characterized by strategic partnerships, mergers, acquisitions, and collaborations aimed at expanding market reach and strengthening research and development efforts. Companies are investing in the development of novel therapies, such as extended half-life products, which offer more convenience for patients with chronic conditions. Additionally, there is an increasing focus on improving the accessibility of plasma protein therapies, including through home care settings, to meet the growing demand in global markets.
List of Leading Companies:
- Grifols
- CSL Behring
- Shire (now part of Takeda)
- Baxter International
- Octapharma
- BioProduct Services
- LFB Group
- Kedrion Biopharma
- Emergent BioSolutions
- Hualan Biological Engineering
- China Biologic Products
- Biotest AG
- Biocryst Pharmaceuticals
- Japanese Red Cross Society
- Albumedix
Recent Developments:
- Grifols announced in January 2025 the launch of a new albumin-based therapeutic for liver diseases, showing promising results in early clinical trials.
- CSL Behring revealed in December 2024 the acquisition of a biopharmaceutical company specializing in hemophilia treatments, enhancing its portfolio in the coagulation factor concentrates segment.
- Shire (Takeda) expanded its immunoglobulin product line in November 2024, introducing a new subcutaneous immunoglobulin (SCIg) formulation for home-based treatment.
- Baxter International launched a new protease inhibitor treatment in October 2024, aimed at improving outcomes in patients with neurological disorders.
- Octapharma entered into a partnership with a research organization in September 2024 to accelerate the development of novel immunoglobulin therapies for immunodeficiency disorders.
Report Scope:
Report Features |
Description |
Market Size (2024-e) |
USD 23.1 Billion |
Forecasted Value (2030) |
USD 40.7 Billion |
CAGR (2025 – 2030) |
9.9% |
Base Year for Estimation |
2024-e |
Historic Year |
2023 |
Forecast Period |
2025 – 2030 |
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
Segments Covered |
Plasma Protein Therapeutics Market by Product Type (Immunoglobulins [Ig], Albumin, Coagulation Factor Concentrates, Protease Inhibitors), by Application (Hemophilia, Immunodeficiency Disorders, Liver Diseases, Neurological Disorders), by End-User (Hospitals, Clinics, Home Care), by Route of Administration (Intravenous [IV], Subcutaneous [SC]) |
Regional Analysis |
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) |
Major Companies |
Grifols, CSL Behring, Shire (now part of Takeda), Baxter International, Octapharma, BioProduct Services, Kedrion Biopharma, Emergent BioSolutions, Hualan Biological Engineering, China Biologic Products, Biotest AG, Biocryst Pharmaceuticals, Albumedix |
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
Frequently Asked Questions
1. Introduction |
1.1. Market Definition |
1.2. Scope of the Study |
1.3. Research Assumptions |
1.4. Study Limitations |
2. Research Methodology |
2.1. Research Approach |
2.1.1. Top-Down Method |
2.1.2. Bottom-Up Method |
2.1.3. Factor Impact Analysis |
2.2. Insights & Data Collection Process |
2.2.1. Secondary Research |
2.2.2. Primary Research |
2.3. Data Mining Process |
2.3.1. Data Analysis |
2.3.2. Data Validation and Revalidation |
2.3.3. Data Triangulation |
3. Executive Summary |
3.1. Major Markets & Segments |
3.2. Highest Growing Regions and Respective Countries |
3.3. Impact of Growth Drivers & Inhibitors |
3.4. Regulatory Overview by Country |
4. Plasma Protein Therapeutics Market, by Product Type (Market Size & Forecast: USD Million, 2023 – 2030) |
4.1. Immunoglobulins (Ig) |
4.2. Albumin |
4.3. Coagulation Factor Concentrates |
4.4. Protease Inhibitors |
4.5. Others |
5. Plasma Protein Therapeutics Market, by Application (Market Size & Forecast: USD Million, 2023 – 2030) |
5.1. Hemophilia |
5.2. Immunodeficiency Disorders |
5.3. Liver Diseases |
5.4. Neurological Disorders |
5.5. Others |
6. Plasma Protein Therapeutics Market, by End-User (Market Size & Forecast: USD Million, 2023 – 2030) |
6.1. Hospitals |
6.2. Clinics |
6.3. Home Care |
6.4. Others |
7. Plasma Protein Therapeutics Market, by Route of Administration (Market Size & Forecast: USD Million, 2023 – 2030) |
7.1. Intravenous (IV) |
7.2. Subcutaneous (SC) |
7.3. Others |
8. Regional Analysis (Market Size & Forecast: USD Million, 2023 – 2030) |
8.1. Regional Overview |
8.2. North America |
8.2.1. Regional Trends & Growth Drivers |
8.2.2. Barriers & Challenges |
8.2.3. Opportunities |
8.2.4. Factor Impact Analysis |
8.2.5. Technology Trends |
8.2.6. North America Plasma Protein Therapeutics Market, by Product Type |
8.2.7. North America Plasma Protein Therapeutics Market, by Application |
8.2.8. North America Plasma Protein Therapeutics Market, by End-User |
8.2.9. North America Plasma Protein Therapeutics Market, by Route of Administration |
8.2.10. By Country |
8.2.10.1. US |
8.2.10.1.1. US Plasma Protein Therapeutics Market, by Product Type |
8.2.10.1.2. US Plasma Protein Therapeutics Market, by Application |
8.2.10.1.3. US Plasma Protein Therapeutics Market, by End-User |
8.2.10.1.4. US Plasma Protein Therapeutics Market, by Route of Administration |
8.2.10.2. Canada |
8.2.10.3. Mexico |
*Similar segmentation will be provided for each region and country |
8.3. Europe |
8.4. Asia-Pacific |
8.5. Latin America |
8.6. Middle East & Africa |
9. Competitive Landscape |
9.1. Overview of the Key Players |
9.2. Competitive Ecosystem |
9.2.1. Level of Fragmentation |
9.2.2. Market Consolidation |
9.2.3. Product Innovation |
9.3. Company Share Analysis |
9.4. Company Benchmarking Matrix |
9.4.1. Strategic Overview |
9.4.2. Product Innovations |
9.5. Start-up Ecosystem |
9.6. Strategic Competitive Insights/ Customer Imperatives |
9.7. ESG Matrix/ Sustainability Matrix |
9.8. Manufacturing Network |
9.8.1. Locations |
9.8.2. Supply Chain and Logistics |
9.8.3. Product Flexibility/Customization |
9.8.4. Digital Transformation and Connectivity |
9.8.5. Environmental and Regulatory Compliance |
9.9. Technology Readiness Level Matrix |
9.10. Technology Maturity Curve |
9.11. Buying Criteria |
10. Company Profiles |
10.1. Grifols |
10.1.1. Company Overview |
10.1.2. Company Financials |
10.1.3. Product/Service Portfolio |
10.1.4. Recent Developments |
10.1.5. IMR Analysis |
*Similar information will be provided for other companies |
10.2. CSL Behring |
10.3. Shire (now part of Takeda) |
10.4. Baxter International |
10.5. Octapharma |
10.6. BioProduct Services |
10.7. LFB Group |
10.8. Kedrion Biopharma |
10.9. Emergent BioSolutions |
10.10. Hualan Biological Engineering |
10.11. China Biologic Products |
10.12. Biotest AG |
10.13. Biocryst Pharmaceuticals |
10.14. Japanese Red Cross Society |
10.15. Albumedix |
11. Appendix |
A comprehensive market research approach was employed to gather and analyze data on the Plasma Protein Therapeutics Market . In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Plasma Protein Therapeutics Market . The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
Secondary Research
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary Research
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the E-Waste Management ecosystem. The primary research objectives included:
- Validating findings and assumptions derived from secondary research
- Gathering qualitative and quantitative data on market trends, drivers, and challenges
- Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
- Assessing the supply-side landscape, including technological advancements and recent developments
Market Size Assessment
A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Plasma Protein Therapeutics Market . These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:
- Identification of key industry players and relevant revenues through extensive secondary research
- Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
- Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources
Data Triangulation
To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.